Von Hippel-Lindau (VHL) Syndrome Overview
Learn About Von Hippel-Lindau (VHL) Syndrome
Von Hippel-Lindau syndrome is an inherited disorder characterized by the formation of tumors and fluid-filled sacs (cysts) in many different parts of the body. Tumors may be either noncancerous or cancerous and most frequently appear during young adulthood; however, the signs and symptoms of von Hippel-Lindau syndrome can occur throughout life.
Mutations in the VHL gene cause von Hippel-Lindau syndrome. The VHL gene is a tumor suppressor gene, which means it keeps cells from growing and dividing too rapidly or in an uncontrolled way. Mutations in this gene prevent production of the VHL protein or lead to the production of an abnormal version of the protein. An altered or missing VHL protein cannot effectively regulate cell survival and division. As a result, cells grow and divide uncontrollably to form the tumors and cysts that are characteristic of von Hippel-Lindau syndrome.
The incidence of von Hippel-Lindau syndrome is estimated to be 1 in 36,000 individuals.
Mutations in the VHL gene are inherited in an autosomal dominant pattern, which means that one copy of the altered gene in each cell is sufficient to increase the risk of developing tumors and cysts. Most people with von Hippel-Lindau syndrome inherit an altered copy of the gene from an affected parent. In about 20 percent of cases, however, the altered gene is the result of a new mutation that occurred during the formation of reproductive cells (eggs or sperm) or very early in development.
Umberto Capitanio practices in Milan, Italy. Mr. Capitanio is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Von Hippel-Lindau (VHL) Syndrome, Nephrectomy, and Prostatectomy.
Francesco Montorsi practices in Milan, Italy. Mr. Montorsi is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Prostate Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Cystectomy.
Kan Gong practices in Beijing, China. Mr. Gong is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Von Hippel-Lindau (VHL) Syndrome, Renal Cell Carcinoma (RCC), Hemangioblastoma, Nephrectomy, and Thrombectomy.
Summary: The study is a phase 2, non-comparative and non-randomized, single arm, national clinical trial testing the hypothesis that CAIX-PET has diagnostic and theranostic potential in VHL disease and in VHL-/- tumors. Participants will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently will be subjected to imaging with an hybrid PET/CT scanner. Sensit...
Summary: NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility...
Published Date: October 01, 2018
Published By: National Institutes of Health

